AbbVie Signs an Exclusive Worldwide Option and License Agreement with Alpine to Develop and Commercialize ALPN-101

 AbbVie Signs an Exclusive Worldwide Option and License Agreement with Alpine to Develop and Commercialize ALPN-101

AbbVie Signs an Exclusive Worldwide Option and License Agreement with Alpine to Develop and Commercialize ALPN-101

Shots:

  • Alpine to receive $60M up front, ~$805M as option exercise fee, development, regulatory and commercial milestones along with royalties on net sales of ALPN-101
  • AbbVie to get an option to exclusively license ALPN-101, following exercising the option, AbbVie will conduct all future clinical development, manufacturing, and commercialization activities for ALPN-101
  • During the option period, Alpine will conduct a P-II study in systemic lupus erythematosus. ALPN-101 is a first in class dual CD28/ICOS co-stimulation antagonist which demonstrated efficacy in multiple preclinical disease models, superior to blockade of either pathway alone

Click here to read full press release/ article | Ref: Alpine | Image: AbbVie

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post